glp 1 agonist nash Treatment with a GLP-1R alleviates NASH-like features in mice Frontiers | Future Perspectives on
Description
GIPR, GIP receptor
Glucagon-like peptide-1 receptor agonists and major adverse cardiovascular events in patients with and without diabetes: a meta-analysis of randomized-controlled trials
Theres a second issue: GLP-1 drugs can trigger the release of enzymes that are associated with pancreatic disorders
The linear peptide is covalently bound to a C20 fatty diacid moiety at the side chain of the Lys20 amino acid (57)
doi: 10.1016/j.bmcl.2007.06.086
J Alzheimers Dis (2013) 37(3):62335
